PTGER4

Summary

PTGER4 (prostaglandin E receptor 4, HGNC:9596) is a protein-coding gene on chromosome 5p13.1, encoding Prostaglandin E2 receptor EP4 subtype (P35408). Receptor for prostaglandin E2 (PGE2).

The protein encoded by this gene is a member of the G-protein coupled receptor family. This protein is one of four receptors identified for prostaglandin E2 (PGE2). This receptor can activate T-cell factor signaling. It has been shown to mediate PGE2 induced expression of early growth response 1 (EGR1), regulate the level and stability of cyclooxygenase-2 mRNA, and lead to the phosphorylation of glycogen synthase kinase-3. Knockout studies in mice suggest that this receptor may be involved in the neonatal adaptation of circulatory system, osteoporosis, as well as initiation of skin immune responses.

Source: NCBI Gene 5734 — RefSeq curated summary.

At a glance

• GWAS associations: 29
• Clinical variants (ClinVar): 77 total
• Druggable target: yes — 9 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_000958

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9596
Approved symbol	PTGER4
Name	prostaglandin E receptor 4
Location	5p13.1
Locus type	gene with protein product
Status	Approved
Aliases	EP4
Ensembl gene	ENSG00000171522
Ensembl biotype	protein_coding
OMIM	601586
Entrez	5734

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 4 protein_coding_CDS_not_defined, 2 protein_coding

ENST00000302472, ENST00000509543, ENST00000512578, ENST00000513635, ENST00000514343, ENST00000963428

RefSeq mRNA: 1 — MANE Select: NM_000958 NM_000958

CCDS: CCDS3930

Canonical transcript exons

ENST00000302472 — 3 exons

Exon	Start	End
ENSE00001143202	40691779	40693735
ENSE00001143213	40680951	40681860
ENSE00002024751	40679915	40680478

Expression profiles

Bgee: expression breadth ubiquitous, 266 present calls, max score 98.94.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 26.1792 / max 880.8595, expressed in 1433 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
56230	22.9924	1361
56232	0.9865	120
56227	0.8471	332
56233	0.6239	219
56228	0.2674	117
56229	0.2565	106
56231	0.1783	57
203535	0.0270	11

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
palpebral conjunctiva	UBERON:0001812	98.94	gold quality
jejunal mucosa	UBERON:0000399	98.00	gold quality
renal glomerulus	UBERON:0000074	97.72	gold quality
mucosa of sigmoid colon	UBERON:0004993	97.46	gold quality
metanephric glomerulus	UBERON:0004736	97.31	gold quality
bronchial epithelial cell	CL:0002328	96.91	gold quality
colonic mucosa	UBERON:0000317	96.73	gold quality
visceral pleura	UBERON:0002401	95.71	gold quality
synovial joint	UBERON:0002217	95.65	gold quality
pleura	UBERON:0000977	95.55	gold quality
germinal epithelium of ovary	UBERON:0001304	95.38	gold quality
epithelium of bronchus	UBERON:0002031	95.31	gold quality
parietal pleura	UBERON:0002400	95.31	gold quality
bronchus	UBERON:0002185	95.14	gold quality
superficial temporal artery	UBERON:0001614	94.87	gold quality
jejunum	UBERON:0002115	94.04	gold quality
lower lobe of lung	UBERON:0008949	93.81	gold quality
mammary duct	UBERON:0001765	93.49	gold quality
mucosa of urinary bladder	UBERON:0001259	93.47	gold quality
vena cava	UBERON:0004087	93.31	gold quality
duodenum	UBERON:0002114	93.30	gold quality
skin of hip	UBERON:0001554	93.05	gold quality
trabecular bone tissue	UBERON:0002483	93.03	gold quality
epithelium of mammary gland	UBERON:0003244	92.66	gold quality
granulocyte	CL:0000094	92.34	gold quality
mucosa of paranasal sinus	UBERON:0005030	91.93	gold quality
leukocyte	CL:0000738	91.44	gold quality
layer of synovial tissue	UBERON:0007616	91.40	gold quality
mononuclear cell	CL:0000842	91.23	gold quality
bone marrow	UBERON:0002371	91.11	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-CURD-46	yes	45.44
E-CURD-88	yes	39.78
E-CURD-122	yes	36.58
E-CURD-77	no	608.36
E-MTAB-5061	no	4.29
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CEBPB, CEBPG, FOXC1, HOXA10, NFKB1, PPARD, RELA, SNAI1, SP1, STAT3, TCF3, TFAP2A, XBP1

miRNA regulators (miRDB)

115 targeting PTGER4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-1229-3P	99.97	66.49	906
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753

Literature-anchored findings (GeneRIF, showing 40)

• Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. (PMID:11782353)
• Placentally derived prostaglandin E2 acts via the EP4 receptor to inhibit IL-2-dependent proliferation of CTLL-2 T cells. (PMID:11876748)
• Increased PGE(2) synthesis in the adjacent stroma and its biological effect via EP(4) on the carcinoma cells may contribute to tumor growth and progression of gallbladder carcinoma. (PMID:11948128)
• effects of PGE2 on monocyte-derived dendritic cells were mediated through increased cyclic adenosine monophosphate by 2 of the known PGE2 receptors, EP2 and EP4 (PMID:12149218)
• endogenous PGE(2) may modulate inflammation during atherogenesis and other inflammatory diseases by suppressing macrophage-derived chemokine production via the EP4 receptor (PMID:12215436)
• Activation of prostaglandin E2-receptor EP2 and EP4 pathways induces growth inhibition in human gastric carcinoma cell lines. (PMID:12228765)
• activation of PI3K/ERK signaling by the EP(4) receptors induces the functional expression of early growth response factor-1 (EGR-1). (PMID:12566441)
• COX-2 induction by bradykinin in human pulmonary artery smooth muscle cells is mediated by the cyclic AMP response element through a novel autocrine loop involving endogenous prostaglandin E2, EP2 receptor, and EP4 receptor (PMID:14517215)
• both beta-arrestin1 recruitment and the presence of Ser/Thr residues in the distal half of the C-terminal domain were necessary for maximal agonist-induced internalization (PMID:14709160)
• Vascular COX-2 was colocalized with prostaglandin E(2) EP4 receptors but not with EP2 receptors in kidney (PMID:15100359)
• EP3 and EP4 mediate different actions of PGE2 on mature human osteoclasts. Activation of EP4 receptors inhibits actin ring formation and activation of EP3 receptors increases number of lamellipodia. (PMID:15290741)
• Endothelin-1-induced prostaglandin E2-EP2 and EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion (PMID:15347673)
• Prostaglandin (PG)E2 induces an increase in intracellular cyclic AMP concentration in the T-leukemic cell line Jurkat via the E-prostanoid (EP)3 receptor. (PMID:15528329)
• PGE2 increases VEGF transcriptionally and involves the Sp-1 binding site via a cAMP-dependent mechanism involving EP2 and EP4 receptors (PMID:15970595)
• EP4 overexpression is associated with enhanced inflammatory reaction in atherosclerotic plaques (PMID:16020747)
• We concluded that PGE2 stimulates the BNP promoter mainly via EP4, PKA, Rap, and p42/44 MAPK. (PMID:16428339)
• seminal plasma and PGE(2) can promote the expression of tumorigenic and angiogenic factors, in cervical adenocarcinoma cells via the EP4 receptor, EGFR, and ERK1/2 signaling pathways (PMID:16574793)
• Presumably plays a key role for active patency of the human ductus arteriosus in the third trimester. (PMID:16857763)
• The EP4 receptor mediates IL-1 beta-induced catabolic metabolism via the p38 MAP kinase pathway in human tendon fibroblasts and may play a major role in the tendon’s degenerative changes often seen in the later stages of tendinopathy. (PMID:17046175)
• Elevated activity in colorectal cancer cells increases resistance to spontaneous apoptosis and promotes anchorage-independent growth, but has no effect on proliferation. (PMID:17130837)
• EP4 mRNA was significantly higher in normal colon tissue compared with tumor tissue. (PMID:17290397)
• Genetic variants associated with Crohn disease risk in a locus modulating cis-acting regulatory elements of PTGER4. (PMID:17447842)
• participates in placentation through EVT invasion by up-regulating PGE2 production and PGE2 receptor expression in first trimester extravillous trophoblasts (PMID:17525067)
• Results show co-expression of cyclooxygenase-2 and prostaglandin E2 receptors EP1, 2 and 4 in non-small cell lung cancer cells concomitant with the synthesis of PGE2. (PMID:17611676)
• Results reveal that egr-1 is a target gene of PGE(2) in HCA-7 cells and is regulated via the newly identified EP4/ERK/CREB pathway. (PMID:17631291)
• Expression of prostaglandin E(2) receptors (EP(2), EP(3), EP(4)), prostaglandin D(2) receptor (DP(2)), prostanoid thromboxane A(2) receptor (TP) and to a lesser extent EP(1) were observed in several hair follicle compartments. (PMID:18005048)
• herpes simplex virus type 1 infected mature monocyte-derived dendritic cells demonstrated a dramatic down-regulation of the expression of the EP2 and EP4 receptors (PMID:18086382)
• mRNA expressions of EP4 receptors observed in NCI-H292 cells and human nasal epithelial cells. (PMID:18254372)
• PGE(2)-EP4 signaling augments NF-kappaB1 p105 protein stability through EPRAP after proinflammatory stimulation, limiting macrophage activation. (PMID:18270204)
• CCR7 and the EP2/EP4 receptor signaling pathway are down-stream targets for COX-2 to enhance the migration of breast cancer cells toward LECs and to promote lymphatic invasion (PMID:18319253)
• Of the 4 EP receptor subtypes, smooth muscle cells in the human pulmonary vein express the EP4 and EP1 receptor subtypes. The relaxations induced by PGE2 in this vessel result from the activation of the EP4 receptor. (PMID:18516068)
• level of exptression in nasal polyps reversely correlates with chronic rhinosinusitis associated with bronchial asthma (PMID:18797183)
• The catabolic effects of prostaglandin E2 in osteoarthritis (OA) are specifically mediated via engagement of the EP4 receptor; of the four PGE2 receptors, only EP4 is up-regulated in OA vs normal cartilage. (PMID:18802112)
• PGE(2) induces angiogenesis in prostate cancer through EP2 and EP4. (PMID:18829529)
• EP4 is directly involved in regulation of proliferation and invasion of inflammatory breast cancer cells (PMID:19227010)
• PGE2 acts via prostaglandin receptor EP2- and EP4-mediated signaling and cyclic AMP pathways to up-regulate IL-23 and IL-1 receptor expression. (PMID:19273625)
• EP2 and EP4 receptor inhibition induces apoptosis of human endometriotic cells through suppression of ERK1/2, AKT, NFkappaB, and beta-catenin pathways and activation of intrinsic apoptotic mechanisms (PMID:19407222)
• PGE(2)-stimulated production of Abeta involves EP(4) receptor-mediated endocytosis of PS-1 followed by activation of the gamma-secretase, as well as EP(2) receptor-dependent activation of adenylate cyclase and PKA (PMID:19407341)
• These results suggest that IL-1beta induces EP4 receptor expression in chondrocytes by an autocrine mechanism that increases PGE2 production, whereas it reduces the expression of EP1 and EP2 via direct action. (PMID:19444759)
• The EP4 agonist PF-04475270 is a novel ocular hypotensive compound which is bioavailable following topical dosing and effectively lowers intraocular pressure. (PMID:19445930)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ptger4b	ENSDARG00000035415
danio_rerio	ptger4a	ENSDARG00000059236
mus_musculus	Ptger4	ENSMUSG00000039942
rattus_norvegicus	Ptger4	ENSRNOG00000013240

Paralogs (7): TBXA2R (ENSG00000006638), PTGER3 (ENSG00000050628), PTGFR (ENSG00000122420), PTGER2 (ENSG00000125384), PTGIR (ENSG00000160013), PTGER1 (ENSG00000160951), PTGDR (ENSG00000168229)

Protein

Protein identifiers

Prostaglandin E2 receptor EP4 subtype — P35408 (reviewed: P35408)

Alternative names: Prostanoid EP4 receptor

All UniProt accessions (1): P35408

UniProt curated annotations — full annotation on UniProt →

Function. Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. Has a relaxing effect on smooth muscle. May play an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function.

Subunit / interactions. Interacts with FEM1A.

Subcellular location. Cell membrane.

Tissue specificity. High in intestine and in peripheral blood mononuclear cells; low in lung, kidney, thymus, uterus, vasculature and brain. Not found in liver, heart, retina oe skeletal muscle.

Post-translational modifications. Phosphorylation mediates agonist-mediated desensitization by promoting cytoplasmic retention.

Similarity. Belongs to the G-protein coupled receptor 1 family.

RefSeq proteins (1): NP_000949* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000276	GPCR_Rhodpsn	Family
IPR001244	Prostglndn_DP_rcpt	Family
IPR001758	Prost_EP4_rcpt	Family
IPR008365	Prostanoid_rcpt	Family
IPR017452	GPCR_Rhodpsn_7TM	Domain

Pfam: PF00001

UniProt features (50 total): helix 12, topological domain 8, transmembrane region 7, turn 7, modified residue 4, strand 4, region of interest 2, compositionally biased region 2, chain 1, glycosylation site 1, disulfide bond 1, sequence conflict 1

Structure

Experimental structures (PDB)

10 structures.

PDB	Method	Resolution (Å)
9JQZ	ELECTRON MICROSCOPY	2.65
9JQY	ELECTRON MICROSCOPY	2.92
8GCP	ELECTRON MICROSCOPY	3.1
8GDB	ELECTRON MICROSCOPY	3.1
5YWY	X-RAY DIFFRACTION	3.2
8GD9	ELECTRON MICROSCOPY	3.2
7D7M	ELECTRON MICROSCOPY	3.3
8GDA	ELECTRON MICROSCOPY	3.3
8GCM	ELECTRON MICROSCOPY	3.5
5YHL	X-RAY DIFFRACTION	4.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P35408-F1	71.51	0.38

Antibody-complex structures (SAbDab): 8 — 5YHL, 5YWY, 7D7M, 8GCM, 8GCP, 8GD9, 8GDA, 8GDB

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 374, 377, 379, 382

Disulfide bonds (1): 92–170

Glycosylation sites (1): 7

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-391908	Prostanoid ligand receptors
R-HSA-418555	G alpha (s) signalling events

MSigDB gene sets: 509 (showing top): GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_UP, VERHAAK_AML_WITH_NPM1_MUTATED_DN, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_CONTAINING_COMPLEX_ASSEMBLY, GOBP_ACTIN_FILAMENT_BUNDLE_ORGANIZATION, BENPORATH_ES_WITH_H3K27ME3, MCLACHLAN_DENTAL_CARIES_UP, GOBP_MYELOID_LEUKOCYTE_MIGRATION, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, GOBP_RESPONSE_TO_PROSTAGLANDIN_E, GOBP_INFLAMMATORY_RESPONSE, REACTOME_EICOSANOID_LIGAND_BINDING_RECEPTORS, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOBP_T_CELL_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE, GOBP_CELLULAR_RESPONSE_TO_EXTERNAL_STIMULUS, GOBP_ALPHA_BETA_T_CELL_DIFFERENTIATION

GO Biological Process (25): negative regulation of cytokine production (GO:0001818), positive regulation of cytokine production (GO:0001819), inflammatory response (GO:0006954), immune response (GO:0006955), adenylate cyclase-modulating G protein-coupled receptor signaling pathway (GO:0007188), adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189), adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway (GO:0007193), positive regulation of cytosolic calcium ion concentration (GO:0007204), JNK cascade (GO:0007254), response to mechanical stimulus (GO:0009612), negative regulation of integrin activation (GO:0033624), response to prostaglandin E (GO:0034695), T-helper cell differentiation (GO:0042093), negative regulation of inflammatory response (GO:0050728), positive regulation of inflammatory response (GO:0050729), regulation of stress fiber assembly (GO:0051492), bone development (GO:0060348), ERK1 and ERK2 cascade (GO:0070371), cellular response to mechanical stimulus (GO:0071260), cellular response to prostaglandin E stimulus (GO:0071380), negative regulation of eosinophil extravasation (GO:2000420), MAPK cascade (GO:0000165), signal transduction (GO:0007165), G protein-coupled receptor signaling pathway (GO:0007186), response to lipid (GO:0033993)

GO Molecular Function (4): prostaglandin E receptor activity (GO:0004957), G protein-coupled receptor activity (GO:0004930), prostaglandin receptor activity (GO:0004955), protein binding (GO:0005515)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Eicosanoid ligand-binding receptors	1
GPCR downstream signalling	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytokine production	2
regulation of cytokine production	2
G protein-coupled receptor signaling pathway	2
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	2
MAPK cascade	2
inflammatory response	2
regulation of inflammatory response	2
negative regulation of gene expression	1
negative regulation of multicellular organismal process	1
positive regulation of gene expression	1
positive regulation of multicellular organismal process	1
defense response	1
immune system process	1
response to stimulus	1
adenylate cyclase activity	1
adenylate cyclase activator activity	1
adenylate cyclase inhibitor activity	1
regulation of biological quality	1
response to external stimulus	1
response to abiotic stimulus	1
negative regulation of protein-containing complex assembly	1
integrin activation	1
regulation of integrin activation	1
response to prostaglandin	1
response to alcohol	1
response to ketone	1
CD4-positive, alpha-beta T cell differentiation	1
negative regulation of defense response	1
negative regulation of response to external stimulus	1
positive regulation of defense response	1
positive regulation of response to external stimulus	1
regulation of actin filament bundle assembly	1
stress fiber assembly	1
regulation of actomyosin structure organization	1
skeletal system development	1
animal organ development	1
response to mechanical stimulus	1
cellular response to abiotic stimulus	1
cellular response to external stimulus	1
response to prostaglandin E	1

Protein interactions and networks

STRING

2446 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PTGER4	PTGER1	P34995	976
PTGER4	PTGS2	P35354	884
PTGER4	PTGES	O14684	872
PTGER4	ARRB1	P49407	816
PTGER4	PRKACA	P17612	787
PTGER4	PRKACG	P22612	787
PTGER4	PRKACB	P22694	786
PTGER4	PTGS1	P23219	739
PTGER4	PTGES2	Q9H7Z7	672
PTGER4	PTGER3	P43115	667
PTGER4	FEM1A	Q9BSK4	639
PTGER4	HAS2	Q92819	631
PTGER4	LTC4S	Q16873	625
PTGER4	HPGD	P15428	625
PTGER4	CALB2	P22676	621

IntAct

44 interactions, top by confidence:

A	B	Type	Score
ARRB1	SRC	psi-mi:“MI:0914”(association)	0.620
SRC	PTGER4	psi-mi:“MI:0915”(physical association)	0.400
ACTN4	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
CRADD	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
CFAP298	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
HOPX	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
NUP153	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
PRDX1	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
PSMC1	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
PPP1R3F	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
CDPF1	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
SLC39A8	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
SND1	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
SLBP	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
ST13	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
WDR19	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
ANAPC7	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
ACY3	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
ATXN10	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
BNIP1	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
BIN1	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
CTNND2	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
RNF220	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
RTF2	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
CRY2	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
DPF1	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
DST	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
EHMT2	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
GJC2	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
HMOX1	PTGER4	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (49): PSEN1 (Affinity Capture-Western), PTGER4 (Affinity Capture-Western), PTGER4 (Affinity Capture-Western), PTGER4 (Affinity Capture-RNA), ACTN4 (Two-hybrid), CRADD (Two-hybrid), C21orf59 (Two-hybrid), HOPX (Two-hybrid), NUP153 (Two-hybrid), PRDX1 (Two-hybrid), PSMC1 (Two-hybrid), PPP1R3F (Two-hybrid), CDPF1 (Two-hybrid), SLC39A8 (Two-hybrid), SND1 (Two-hybrid)

ESM2 similar proteins: A5D7K8, O35932, O95136, O95977, P21731, P30557, P30987, P34972, P34978, P34979, P34980, P35375, P35408, P37289, P43088, P43114, P43115, P43116, P43117, P43118, P43119, P43252, P43253, P46069, P47752, P47901, P47936, P50131, P52592, P56486, P70263, P70597, P79393, Q13258, Q28691, Q28905, Q5R949, Q62053, Q62928, Q8MJ08

Diamond homologs: A0A4W3GG95, A0A6I8PUB9, A5PLE7, A7YY44, B0UXR0, B5X337, D4A7K7, E7FEL0, E9QJ73, O00254, O42179, O88634, P25116, P26824, P30558, P30937, P31391, P32240, P32246, P32249, P32250, P35366, P35383, P35408, P41231, P41232, P43114, P43657, P49660, P51436, P51676, P56482, P58826, P97266, Q09QM4, Q13304, Q149R9, Q1RMI1, Q28691, Q2KTE1

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
“prostaglandin E2”	up-regulates	PTGER4	“chemical activation”
PTGER4	“up-regulates activity”	GNAS	binding
PTGER4	“up-regulates activity”	GNAL	binding
PTGER4	“up-regulates activity”	GNAI1	binding
“prostaglandin E2(1-)”	“up-regulates activity”	PTGER4	“chemical activation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

77 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	69
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

605 predictions. Top by Δscore:

Variant	Effect	Δscore
5:40681858:GTG:G	donor_gain	1.0000
5:40681861:G:GG	donor_gain	1.0000
5:40681832:T:TA	donor_gain	0.9900
5:40681833:G:GA	donor_gain	0.9900
5:40681861:GTG:G	donor_loss	0.9900
5:40681862:T:TG	donor_loss	0.9900
5:40681863:G:GT	donor_loss	0.9900
5:40691774:TGCAG:T	acceptor_loss	0.9900
5:40691775:GCAG:G	acceptor_loss	0.9900
5:40691776:CAG:C	acceptor_loss	0.9900
5:40685533:GC:G	donor_gain	0.9800
5:40691778:GGTGC:G	acceptor_gain	0.9800
5:40680225:GCGA:G	donor_gain	0.9700
5:40681857:CGTG:C	donor_gain	0.9700
5:40681858:GTGG:G	donor_gain	0.9700
5:40681859:TG:T	donor_gain	0.9700
5:40681859:TGGT:T	donor_gain	0.9700
5:40681860:GG:G	donor_gain	0.9700
5:40681860:GGTG:G	donor_gain	0.9700
5:40681864:AGTGA:A	donor_loss	0.9700
5:40691777:A:AG	acceptor_gain	0.9700
5:40691778:G:GG	acceptor_gain	0.9700
5:40680229:G:GG	donor_gain	0.9600
5:40681856:TCGTG:T	donor_gain	0.9600
5:40691778:GGT:G	acceptor_gain	0.9600
5:40691774:T:TA	acceptor_gain	0.9500
5:40685534:C:G	donor_gain	0.9400
5:40691770:C:G	acceptor_gain	0.9300
5:40679965:G:GT	donor_gain	0.9100
5:40680949:A:AG	acceptor_gain	0.9100

AlphaMissense

3141 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:40681098:C:A	N35K	1.000
5:40681098:C:G	N35K	1.000
5:40681190:T:C	L66P	1.000
5:40681210:A:C	S73R	1.000
5:40681212:C:A	S73R	1.000
5:40681212:C:G	S73R	1.000
5:40691890:T:A	W327R	1.000
5:40691890:T:C	W327R	1.000
5:40681084:G:A	G31R	0.999
5:40681084:G:C	G31R	0.999
5:40681084:G:T	G31W	0.999
5:40681085:G:A	G31E	0.999
5:40681093:G:C	G34R	0.999
5:40681094:G:A	G34D	0.999
5:40681106:C:A	A38D	0.999
5:40681153:T:C	F54L	0.999
5:40681155:C:A	F54L	0.999
5:40681155:C:G	F54L	0.999
5:40681175:T:C	L61P	0.999
5:40681178:C:A	A62D	0.999
5:40681187:A:C	D65A	0.999
5:40681187:A:G	D65G	0.999
5:40681187:A:T	D65V	0.999
5:40681188:C:A	D65E	0.999
5:40681188:C:G	D65E	0.999
5:40681195:G:C	G68R	0.999
5:40681333:A:C	S114R	0.999
5:40681335:T:A	S114R	0.999
5:40681335:T:G	S114R	0.999
5:40681343:G:C	R117P	0.999

dbSNP variants (sampled 300 via entrez): RS1000074054 (5:40695014 A>G), RS1000102264 (5:40679929 G>A,C), RS1000106105 (5:40742199 T>G), RS1000154750 (5:40741137 T>A), RS1000176147 (5:40694561 T>G), RS1000178110 (5:40713726 A>T), RS1000207940 (5:40738801 G>A), RS1000240468 (5:40739092 T>C), RS1000242889 (5:40717498 A>G), RS1000294253 (5:40700951 A>C), RS1000373435 (5:40707227 C>T), RS1000423515 (5:40741390 C>T), RS1000547078 (5:40737141 C>CA), RS1000548016 (5:40692801 T>C,G), RS1000578047 (5:40737453 A>G)

Disease associations

OMIM: gene MIM:601586 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

29 associations (top):

Study	Trait	p-value
GCST000066_1	Crohn’s disease	4.000000e-07
GCST000207_29	Crohn’s disease	7.000000e-27
GCST000424_12	Multiple sclerosis	2.000000e-07
GCST000879_53	Crohn’s disease	7.000000e-36
GCST000964_16	Ulcerative colitis	3.000000e-09
GCST001149_6	Ankylosing spondylitis	3.000000e-07
GCST001198_70	Multiple sclerosis	3.000000e-16
GCST001300_2	Gastric cancer	8.000000e-29
GCST001438_4	Crohn’s disease	2.000000e-11
GCST001505_1	Multiple sclerosis	1.000000e-09
GCST001652_7	Crohn’s disease	1.000000e-06
GCST001725_81	Inflammatory bowel disease	2.000000e-82
GCST002083_17	Self-reported allergy	8.000000e-11
GCST002992_8	Gastric cancer	5.000000e-06
GCST003097_11	Pediatric autoimmune diseases	8.000000e-11
GCST003814_7	Selective IgA deficiency	5.000000e-07
GCST004290_4	Multiple sclerosis	2.000000e-06
GCST005038_17	Allergic disease (asthma, hay fever or eczema)	6.000000e-10
GCST005529_19	Ankylosing spondylitis	5.000000e-06
GCST005529_37	Ankylosing spondylitis	4.000000e-06
GCST007536_4	Serum urea levels	6.000000e-10
GCST007856_11	Colorectal cancer or advanced adenoma	4.000000e-09
GCST007856_23	Colorectal cancer or advanced adenoma	4.000000e-21
GCST008062_2	Blood urea nitrogen levels	4.000000e-84
GCST008730_1	Crohn’s disease	3.000000e-06
GCST90002403_398	Red blood cell count	6.000000e-09
GCST90011899_183	Aspartate aminotransferase levels	1.000000e-29
GCST90013445_25	Type 1 diabetes	2.000000e-14
GCST90013445_39	Type 1 diabetes	2.000000e-14

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004305	erythrocyte count
EFO:0004736	aspartate aminotransferase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL1836 (SINGLE PROTEIN), CHEMBL2363068 (PROTEIN FAMILY)

Molecules with ChEMBL bioactivity

9 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 19,549 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL548	DINOPROSTONE	4	14,939
CHEMBL815	DINOPROST	4	3,118
CHEMBL3301604	RALINEPAG	3	260
CHEMBL1628698	BGC-20-1531 FREE BASE	2	67
CHEMBL3039498	GRAPIPRANT	2	983
CHEMBL3260771	BGC-20-1531	2	19
CHEMBL3670685	PALUPIPRANT	2	53
CHEMBL3707245	OMIDENEPAG	2	81
CHEMBL5314911	BMS-986310	2	29

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs4133101	Toxicity	3	celecoxib	Colorectal Neoplasms

PharmGKB variants

3 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs4133101	PTGER4	3	2.50	1	celecoxib
rs10512734	PTGER4		0.00	0
rs11749180	PTGER4, TTC33		0.00	0

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Prostanoid receptors

Most potent curated ligand interactions (52 total), top 25:

Ligand	Action	Affinity	Parameter
L902688	Agonist	10.3	pEC50
[3H]PGE2	Full agonist	9.52	pKd
KMN-159	Agonist	9.42	pKi
11-deoxy-PGE1	Agonist	9.33	pEC50
ER819762	Antagonist	9.25	pKi
MK-2894	Antagonist	9.25	pKi
rivenprost	Full agonist	9.2	pKi
MF 498	Antagonist	9.15	pKi
ONO-AE1-437	Agonist	9.15	pKi
11-deoxy-PGE2	Full agonist	9.0	pKi
CP734432	Agonist	9.0	pEC50
TCS 2510	Agonist	8.92	pKi
ONO-AE3-208	Antagonist	8.9	pKi
PGE1	Full agonist	8.8	pKi
PGD2	Full agonist	8.77	pEC50
evatanepag	Antagonist	8.6	pKi
ONO-AE2-227	Antagonist	8.57	pKi
CJ-042794	Antagonist	8.51	pKi
13,14-dihydro-PGE1	Full agonist	8.5	pKi
L-161,982 (EP4A)	Agonist	8.5	pKi
compound 47 [PMID: 35640059]	Antagonist	8.3	pIC50
palupiprant	Antagonist	8.2	pKi
MB-28767	Full agonist	8.0	pKi
BGC201531	Antagonist	7.9	pKi
grapiprant	Antagonist	7.89	pKi

Binding affinities (BindingDB)

340 measured of 403 human assays (405 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
7-[(5R)-3,3-difluoro-5-[(E,3S)-3-hydroxy-7-phenylhept-1-enyl]-2-oxopyrrolidin-1-yl]heptanoic acid	EC50	0.01 nM	US-9180116: Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
7-[(5R)-3,3-difluoro-5-[(E,3S,4S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2-oxopyrrolidin-1-yl]heptanoic acid	EC50	0.059 nM	US-9180116: Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
5-[3-[(5R)-3,3-difluoro-5-[(E,3S,4S)-3-hydroxy-4-methyl-6-phenylhex-1-enyl]-2-oxopyrrolidin-1-yl]propyl]thiophene-2-carboxylic acid	EC50	0.15 nM	US-9180116: Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
4-[2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2,3-dihydroindol-7-yl]ethyl]benzoic acid	KI	0.3 nM	US-9546162: Compounds and methods for skin repair
NSC_5311503	KI	0.3 nM
NSC_3080928	KI	0.4 nM
4-[(1S)-1-[[2,5-dibromo-4-[(3-chlorophenyl)methyl]thiophene-3-carbonyl]amino]ethyl]benzoic acid	KI	0.47 nM	US-8969394: Thiophenecarboxamide derivatives as EP4 receptor ligands
4-{1-[({2,5-Dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}-carbonyl)amino]cyclopropyl}benzoic Acid	KI	0.5 nM	US-8969394: Thiophenecarboxamide derivatives as EP4 receptor ligands
2,5-dimethyl-N-[1-[4-(2H-tetrazol-5-yl)phenyl]cyclopropyl]-4-[[4-(trifluoromethyl)phenyl]methyl]thiophene-3-carboxamide	KI	0.6 nM	US-8969394: Thiophenecarboxamide derivatives as EP4 receptor ligands
2,5-dimethyl-N-[1-[4-(2H-tetrazol-5-yl)phenyl]cyclopropyl]-4-[[3-(trifluoromethyl)phenyl]methyl]thiophene-3-carboxamide	KI	0.7 nM	US-8969394: Thiophenecarboxamide derivatives as EP4 receptor ligands
4-[(1S)-1-[[5-bromo-4-[(3-chlorophenyl)methyl]thiophene-3-carbonyl]amino]ethyl]benzoic acid	KI	0.71 nM	US-8969394: Thiophenecarboxamide derivatives as EP4 receptor ligands
4-[(1S)-1-[[2,5-dichloro-4-[[3-(trifluoromethyl)phenyl]methyl]thiophene-3-carbonyl]amino]ethyl]benzoic acid	KI	0.8 nM	US-8969394: Thiophenecarboxamide derivatives as EP4 receptor ligands
4-{1-[({2,5-Dimethyl-4-[3-(trifluoromethyl)benzyl]-3-thienyl}-carbonyl)amino]cyclopropyl}benzoic Acid	KI	0.8 nM	US-8969394: Thiophenecarboxamide derivatives as EP4 receptor ligands
2-[3-[[5-(3-fluorophenyl)-2-methoxy-3-methylphenyl]methylamino]-2,4-dimethylphenoxy]acetic acid	EC50	0.9 nM	US-9249085: Aniline derivatives, their preparation and their therapeutic application
4-[(1R)-1-({[2,5-Dichloro-4-(3-chlorobenzyl)-3-thienyl]carbonyl}amino)ethyl]benzoic acid	KI	0.9 nM	US-8969394: Thiophenecarboxamide derivatives as EP4 receptor ligands
4-[({[2,5-Dichloro-4-(3-chlorobenzyl)-3-thienyl]carbonyl}amino)methyl]benzoic acid	KI	0.9 nM	US-8969394: Thiophenecarboxamide derivatives as EP4 receptor ligands
4-[4-Cyano-2-({[(1R,2R)-6′-(methylcarbamoyl)-2′,3′-dihydrospiro[cyclopropane-1, 1′-inden]-2-yl]carbonyl}amino)phenyl]butanoic acid	IC50	1.2 nM	US-10077247: Tricyclic spiro compound
4-{4-Cyano-2-[({2′R, 4S)-6-[(1-methyl 1H-pyrazol-4-yl)carbamoyl]-2,3-dihydrospiro[chromene-4,1′-cyclopropan]-2′-yl}carbonyl)amino]phenyl}butanoic acid	IC50	1.3 nM	US-10077247: Tricyclic spiro compound
4-[(1S)-1-({[2,5-Dichloro-4-(3-chlorobenzyl)-3-thienyl]carbonyl}-amino)ethyl]benzoic Acid	KI	1.3 nM	US-8969394: Thiophenecarboxamide derivatives as EP4 receptor ligands
4-{(1S)-1-[({2,5-Dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}-carbonyl)amino]ethyl}benzoic acid	KI	1.4 nM	US-8969394: Thiophenecarboxamide derivatives as EP4 receptor ligands
4-[4-cyano-2-[[(1’R,4S)-7-fluoro-6-(2-methoxyethylcarbamoyl)spiro[2,3-dihydrochromene-4,2’-cyclopropane]-1’-carbonyl]amino]phenyl]butanoic acid	IC50	1.6 nM	US-10077247: Tricyclic spiro compound
CAS_41598-07-6	KI	1.7 nM
4-[(1S)-1-[[2,5-dichloro-4-[(3-chlorophenyl)-hydroxymethyl]thiophene-3-carbonyl]amino]ethyl]benzoic acid	KI	1.8 nM	US-8969394: Thiophenecarboxamide derivatives as EP4 receptor ligands
2-[4-fluoro-3-[[2-fluoro-5-(3-fluorophenyl)-3-methylphenyl]methylamino]-2-methylphenoxy]acetic acid	EC50	2 nM	US-9249085: Aniline derivatives, their preparation and their therapeutic application
2-[3-[[5-(3-fluorophenyl)-2,3-dimethylphenyl]methylamino]-2,4-dimethylphenoxy]acetic acid	EC50	2 nM	US-9249085: Aniline derivatives, their preparation and their therapeutic application
4-[2-[1-[(3-fluorophenyl)methyl]-2,3-dihydroindol-7-yl]ethyl]benzoic acid	KI	2 nM	US-9546162: Compounds and methods for skin repair
4-[4-Cyano-2-({[(2′R,4S)-6-(1H-pyrazol-1-yl)-2,3-dihydrospiro[chromene-4,1′-cyclopropan]-2′-yl]carbonyl}amino)phenyl]butanoic acid	IC50	2.4 nM	US-10077247: Tricyclic spiro compound
4-{(1S)-1-[({2,5-Dimethyl-4-[3-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]ethyl}benzoic Acid	KI	2.4 nM	US-8969394: Thiophenecarboxamide derivatives as EP4 receptor ligands
4-[4-cyano-2-[[(1’R,4S)-6-(methylcarbamoyl)spiro[2,3-dihydrochromene-4,2’-cyclopropane]-1’-carbonyl]amino]phenyl]butanoic acid	IC50	2.5 nM	US-10077247: Tricyclic spiro compound
4-[4-Cyano-2-({[(2′R,4S)-6-(3-pyridazinylcarbamoyl)-2,3-dihydrospiro[chromene-4,1′-cyclopropan]-2′-yl]carbonyl}amino)phenyl]butanoic acid	IC50	2.5 nM	US-10077247: Tricyclic spiro compound
4-[4-Cyano-2-({[(2′R,4S)-6-(propylcarbamoyl)-2,3-dihydrospiro[chromene-4,1′-cyclopropan]-2′-yl]carbonyl}amino)phenyl]butanoic acid	IC50	2.5 nM	US-10077247: Tricyclic spiro compound
5-chloro-3-[(3-chlorophenyl)methyl]-N-[1-[4-(2H-tetrazol-5-yl)phenyl]ethyl]thiophene-2-carboxamide	KI	2.6 nM	US-8969394: Thiophenecarboxamide derivatives as EP4 receptor ligands
4-[4-Cyano-2-({[(2′R,4S)-6-(5-methyl-1,3,4-oxadiazol-2-yl)-2,3-dihydrospiro[chromene-4,1′-cyclopropan]-2′-yl]carbonyl}amino)phenyl]butanoic acid	IC50	2.7 nM	US-10077247: Tricyclic spiro compound
4-{4-Cyano-2-[({(1R,2R)-6′-[(1-methyl-1H-pyrazol-4-yl)carbamoyl]-2′,3′-dihydrospiro[cyclopropane-1,1′-inden]-2-yl}carbonyl)amino]phenyl}butanoic acid	IC50	2.7 nM	US-10077247: Tricyclic spiro compound
4-[4-cyano-2-[[(1’R,4S)-6-(3-methyl-1,2,4-oxadiazol-5-yl)spiro[2,3-dihydrochromene-4,2’-cyclopropane]-1’-carbonyl]amino]phenyl]butanoic acid	IC50	2.8 nM	US-10077247: Tricyclic spiro compound
2-[2,4-difluoro-3-[[3-fluoro-5-(3-fluorophenyl)-2-methylphenyl]methylamino]phenoxy]acetic acid	EC50	3 nM	US-9249085: Aniline derivatives, their preparation and their therapeutic application
2-[3-[[3-fluoro-5-(3-fluorophenyl)-2-methylphenyl]methylamino]-2,4-dimethylphenoxy]acetic acid	EC50	3 nM	US-9249085: Aniline derivatives, their preparation and their therapeutic application
4-[4-Cyano-2-({[(2′R,4S)-6-(ethylcarbamoyl)-2,3-dihydrospiro[chromene-4,1′-cyclopropan]-2′-yl]carbonyl}amino)phenyl]butanoic acid	IC50	3 nM	US-10077247: Tricyclic spiro compound
4-{4-Cyano-2-[({(1R,2R)-6′-[(2-methoxyethyl)carbamoyl]-2′,3′-dihydrospiro[cyclopropane-1,1′-inden]-2-yl}carbonyl)amino]phenyl}butanoic acid	IC50	3 nM	US-10077247: Tricyclic spiro compound
4-[(1S)-1-({[4-(3-Chlorobenzyl)-2,5-dimethyl-3-thienyl]carbonyl}-amino)ethyl]benzoic Acid	KI	3.1 nM	US-8969394: Thiophenecarboxamide derivatives as EP4 receptor ligands
4-[4-cyano-2-[[(1’R,4S)-6-[[(2S)-1-methoxypropan-2-yl]carbamoyl]spiro[2,3-dihydrochromene-4,2’-cyclopropane]-1’-carbonyl]amino]phenyl]butanoic acid	IC50	3.3 nM	US-10077247: Tricyclic spiro compound
4-[4-Cyano-2-({[(2′R,4S)-6-(1,2-oxazol-3-ylcarbamoyl)-2,3-dihydrospiro[chromene-4,1′-cyclopropan]-2′-yl]carbonyl}amino)phenyl]butanoic acid	IC50	3.4 nM	US-10077247: Tricyclic spiro compound
4-[2-[[(1’R,4S)-6-[(1-tert-butylpyrazol-4-yl)carbamoyl]spiro[2,3-dihydrochromene-4,2’-cyclopropane]-1’-carbonyl]amino]-4-cyanophenyl]butanoic acid	IC50	3.4 nM	US-10077247: Tricyclic spiro compound
4-[4-Cyano-2-({[(2′R,4S)-6-(1,2-oxazol-5-ylcarbamoyl)-2,3-dihydrospiro[chromene-4,1′-cyclopropan]-2′-yl]carbonyl}amino)phenyl]butanoic acid	IC50	3.4 nM	US-10077247: Tricyclic spiro compound
4-[(1S)-1-({[4-(4-Chlorobenzyl)-2,5-dimethyl-3-thienyl]carbonyl}-amino)ethyl]benzoicAcid	KI	3.4 nM	US-8969394: Thiophenecarboxamide derivatives as EP4 receptor ligands
4-[2-[[(1’R,4S)-6-(tert-butylcarbamoyl)spiro[2,3-dihydrochromene-4,2’-cyclopropane]-1’-carbonyl]amino]-4-cyanophenyl]butanoic acid	IC50	3.5 nM	US-10077247: Tricyclic spiro compound
4-[4-Cyano-2-({[(2′R,4S)-6-(6-methoxy-3-pyridinyl)-2,3-dihydrospiro[chromene-4, 1′-cyclopropan]-2′-yl]carbonyl}amino)phenyl]butanoic acid	IC50	3.5 nM	US-10077247: Tricyclic spiro compound
4-[4-Cyano-2-({[(2′R,4S)-6-(1-methyl-1H-1,2,3-triazol-4-yl)-2,3-dihydrospiro[chromene-4,1′-cyclopropan]-2′-yl]carbonyl}amino)phenyl]butanoic acid	IC50	3.5 nM	US-10077247: Tricyclic spiro compound
4-{4-Cyano-2-[({(2′R,4S)-6-[(1-methyl-1H-pyrazol-5-yl)carbamoyl]-2, 3-dihydrospiro[chromene-4,1′-cyclopropan]-2′-yl}carbonyl)amino]phenyl}butanoic acid	IC50	3.6 nM	US-10077247: Tricyclic spiro compound
4-{4-Cyano-2-[({(2′R,4S)-6-[(2,2-difluoroethyl)carbamoyl]-2,3-dihydrospiro[chromene-4,1′-cyclopropan]-2′-yl}carbonyl)amino]phenyl}butanoic acid	IC50	3.7 nM	US-10077247: Tricyclic spiro compound

ChEMBL bioactivities

1744 potent at pChembl≥5 of 1778 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
11.00	EC50	0.01	nM	CHEMBL3975743
11.00	EC50	0.01	nM	CHEMBL3959605
11.00	EC50	0.01	nM	CHEMBL292964
10.85	EC50	0.014	nM	CHEMBL5945805
10.79	EC50	0.0162	nM	CHEMBL3937596
10.72	EC50	0.019	nM	CHEMBL5838727
10.70	EC50	0.02	nM	DINOPROSTONE
10.70	Ki	0.02	nM	CHEMBL258332
10.70	EC50	0.02	nM	CHEMBL222715
10.70	EC50	0.02	nM	CHEMBL5436415
10.68	EC50	0.021	nM	CHEMBL3955128
10.64	EC50	0.023	nM	CHEMBL3897335
10.52	EC50	0.03	nM	CHEMBL258332
10.52	EC50	0.03	nM	CHEMBL272276
10.46	EC50	0.035	nM	CHEMBL3895047
10.42	EC50	0.038	nM	CHEMBL3902065
10.42	EC50	0.038	nM	CHEMBL3918816
10.40	EC50	0.04	nM	CHEMBL3974652
10.40	EC50	0.04	nM	CHEMBL222677
10.40	EC50	0.04	nM	CHEMBL251294
10.33	EC50	0.047	nM	CHEMBL3895047
10.30	EC50	0.05	nM	CHEMBL64804
10.30	EC50	0.05	nM	CHEMBL3906016
10.30	Ki	0.05	nM	CHEMBL272276
10.30	EC50	0.05	nM	CHEMBL5395111
10.23	EC50	0.059	nM	CHEMBL3893847
10.23	EC50	0.059	nM	CHEMBL3982139
10.23	EC50	0.059	nM	CHEMBL3955128
10.20	EC50	0.063	nM	CHEMBL3916499
10.19	EC50	0.065	nM	CHEMBL42027
10.12	EC50	0.075	nM	CHEMBL3923027
10.10	EC50	0.079	nM	CHEMBL3916499
10.09	Ki	0.082	nM	CHEMBL3923027
10.06	EC50	0.088	nM	CHEMBL3918816
10.00	EC50	0.1	nM	CHEMBL3960625
10.00	Ki	0.1	nM	CHEMBL3916499
10.00	EC50	0.1	nM	CHEMBL251505
10.00	EC50	0.1	nM	CHEMBL249953
9.96	EC50	0.11	nM	CHEMBL3949856
9.96	Ki	0.11	nM	DINOPROSTONE
9.96	Ki	0.11	nM	CHEMBL1669013
9.92	Ki	0.12	nM	CHEMBL3895047
9.92	Ki	0.12	nM	CHEMBL256873
9.85	Ki	0.14	nM	CHEMBL64804
9.85	EC50	0.142	nM	CHEMBL292964
9.85	Ki	0.14	nM	DINOPROSTONE
9.82	EC50	0.15	nM	CHEMBL3982139
9.82	EC50	0.15	nM	CHEMBL3891907
9.80	Ki	0.16	nM	CHEMBL1669017
9.80	Ki	0.16	nM	CHEMBL1669012

PubChem BioAssay actives

1129 with measured affinity, of 1722 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
7-[(2R)-2-[(E,3S)-3-hydroxy-4-phenylbut-1-enyl]-5-oxopyrrolidin-1-yl]heptanoic acid	1970857: Agonist activity at EP4 (unknown origin) assessed as increase in calcium flux	ec50	<0.0001	uM
4-[2-[(2R)-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxopyrrolidin-1-yl]ethyl]benzoic acid	320754: Agonist activity at human EP4 receptor by cAMP assay	ec50	<0.0001	uM
4-[2-[(2S)-2-[(3R)-3-[3-(4-chloro-2-methylphenyl)phenyl]-3-hydroxypropyl]-5-oxopyrrolidin-1-yl]ethyl]benzoic acid	281511: Functional activity at human EP4 receptor	ec50	<0.0001	uM
4-[2-[(2R)-2-[(E,3S)-3-hydroxyhept-1-enyl]-5-oxopyrrolidin-1-yl]ethyl]benzoic acid	308197: Agonist activity at EP4 receptor expressed in HEK293 cells assessed as cAMP accumulation	ec50	<0.0001	uM
4-[2-[(2R)-2-[(E,3S)-4-(3-chlorophenyl)-3-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl]ethyl]benzoic acid	320753: Displacement of [3H]PGE4 from human EP4 receptor	ki	<0.0001	uM
dinoprostone	1587874: Agonist activity at human EP4 receptor expressed in HEK293T/17 cells assessed as increase in GalphaS-mediated CREB activation measured after 6 to 24 hrs by SEAP reporter gene-based chemiluminescence assay	ec50	<0.0001	uM
7-[(5R)-3,3-difluoro-5-[(E,3S)-3-hydroxyoct-1-enyl]-2-oxopyrrolidin-1-yl]heptanoic acid	1587874: Agonist activity at human EP4 receptor expressed in HEK293T/17 cells assessed as increase in GalphaS-mediated CREB activation measured after 6 to 24 hrs by SEAP reporter gene-based chemiluminescence assay	ec50	<0.0001	uM
4-[2-[(2R)-2-[(E,3S)-3-hydroxy-4-phenylbut-1-enyl]-5-oxopyrrolidin-1-yl]ethyl]benzoic acid	320754: Agonist activity at human EP4 receptor by cAMP assay	ec50	<0.0001	uM
4-[2-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl]-5-oxocyclopentyl]ethylsulfanyl]butanoic acid	1587874: Agonist activity at human EP4 receptor expressed in HEK293T/17 cells assessed as increase in GalphaS-mediated CREB activation measured after 6 to 24 hrs by SEAP reporter gene-based chemiluminescence assay	ec50	<0.0001	uM
N-benzylsulfonyl-7-[(2R)-2-[(E,3S)-3-hydroxy-4-phenylbut-1-enyl]-5-oxopyrrolidin-1-yl]heptanamide	1970857: Agonist activity at EP4 (unknown origin) assessed as increase in calcium flux	ec50	0.0001	uM
7-[(2R)-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxopyrrolidin-1-yl]heptanoic acid	1587874: Agonist activity at human EP4 receptor expressed in HEK293T/17 cells assessed as increase in GalphaS-mediated CREB activation measured after 6 to 24 hrs by SEAP reporter gene-based chemiluminescence assay	ec50	0.0001	uM
4-[2-[(2R)-2-[(1E,3Z)-4-methylocta-1,3-dienyl]-5-oxopyrrolidin-1-yl]ethyl]benzoic acid	308197: Agonist activity at EP4 receptor expressed in HEK293 cells assessed as cAMP accumulation	ec50	0.0001	uM
4-[2-[2-[(3S)-4-(3-bromophenyl)-3-hydroxybutyl]-5-oxopyrazolidin-1-yl]ethyl]benzoic acid	310293: Agonist activity at human prostaglandin EP4 receptor	ec50	0.0001	uM
2-(2-acetyl-6-methoxyphenyl)-N-[[4-(5,9-diethoxy-6-oxo-8H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylphenyl]methylsulfonyl]acetamide	316652: Binding affinity to human EP4 receptor expressed in HEK293 cells	ki	0.0001	uM
1-[1-[[4-(4,9-diethoxy-3-oxo-1H-benzo[f]isoindol-2-yl)-3-methylphenyl]methyl]cyclopropyl]-3-(4-methylphenyl)sulfonylurea	568519: Antagonist activity at human EP4 receptor expressed in HEK293 cells assessed as PGE2-induced cAMP accumulation by scintillation proximity assay	ki	0.0001	uM
7-[(5R)-3,3-difluoro-5-[(E,3S,4S)-3-hydroxy-4-methylnon-1-en-6-ynyl]-2-oxopyrrolidin-1-yl]heptanoic acid	1587874: Agonist activity at human EP4 receptor expressed in HEK293T/17 cells assessed as increase in GalphaS-mediated CREB activation measured after 6 to 24 hrs by SEAP reporter gene-based chemiluminescence assay	ec50	0.0001	uM
4-[2-[2-[4-(3-chlorophenyl)-3-hydroxybutyl]-5-oxopyrazolidin-1-yl]ethyl]benzoic acid	310293: Agonist activity at human prostaglandin EP4 receptor	ec50	0.0002	uM
4-[2-[2-[4-(3-bromophenyl)-3-hydroxybutyl]-5-oxopyrazolidin-1-yl]ethyl]benzoic acid	310293: Agonist activity at human prostaglandin EP4 receptor	ec50	0.0002	uM
4-[2-[(2R)-2-[(E,3S)-5-cyclobutyl-3-hydroxypent-1-enyl]-5-oxopyrrolidin-1-yl]ethyl]benzoic acid	281511: Functional activity at human EP4 receptor	ec50	0.0002	uM
N-[[4-(5,9-diethoxy-6-oxo-8H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylphenyl]methylsulfonyl]-2-[2-(trifluoromethoxy)phenyl]acetamide	316652: Binding affinity to human EP4 receptor expressed in HEK293 cells	ki	0.0002	uM
4-[(1S)-1-[[1-[[3-(trifluoromethyl)phenyl]methyl]-2,3-dihydroindole-7-carbonyl]amino]ethyl]benzoic acid	549652: Agonist activity at human prostanoid EP4 receptor expressed in HEK293 cells assessed as potentiation of PGE2-induced cAMP accumulation by scintillation proximity assay	ec50	0.0002	uM
4-[1-[[1-[[4-(trifluoromethyl)phenyl]methyl]indole-7-carbonyl]amino]cyclopropyl]benzoic acid	484030: Displacement of [3H]PGE2 from human prostanoid EP4 receptor expressed in HEK293-EBNA cells after 60 mins by scintillation counting	ki	0.0002	uM
1-(2-chlorophenyl)sulfonyl-3-[1-[[4-(4,9-diethoxy-3-oxo-1H-benzo[f]isoindol-2-yl)-3-methylphenyl]methyl]cyclopropyl]urea	568519: Antagonist activity at human EP4 receptor expressed in HEK293 cells assessed as PGE2-induced cAMP accumulation by scintillation proximity assay	ki	0.0002	uM
1-[1-[[4-(4,9-diethoxy-3-oxo-1H-benzo[f]isoindol-2-yl)-3-methylphenyl]methyl]cyclopropyl]-3-(2-methylphenyl)sulfonylurea	568519: Antagonist activity at human EP4 receptor expressed in HEK293 cells assessed as PGE2-induced cAMP accumulation by scintillation proximity assay	ki	0.0002	uM
1-[1-[[4-(4,9-diethoxy-3-oxo-1H-benzo[f]isoindol-2-yl)-3-methylphenyl]methyl]cyclopropyl]-3-(2-methoxyphenyl)sulfonylurea	568519: Antagonist activity at human EP4 receptor expressed in HEK293 cells assessed as PGE2-induced cAMP accumulation by scintillation proximity assay	ki	0.0002	uM
3-[4-[2-[[2-(2-methoxyphenyl)acetyl]amino]ethyl]phenyl]-N,N,5,7-tetramethyl-1-benzothiophene-2-carboxamide	552143: Binding affinity to EP4 receptor	ki	0.0002	uM
N-[1-[[4-(4,9-diethoxy-3-oxo-1H-benzo[f]isoindol-2-yl)-3-methylphenyl]methyl]cyclopropyl]-2-(2-methoxyphenyl)acetamide	568519: Antagonist activity at human EP4 receptor expressed in HEK293 cells assessed as PGE2-induced cAMP accumulation by scintillation proximity assay	ki	0.0002	uM
3-[2-[[1-[[4-(4,9-diethoxy-3-oxo-1H-benzo[f]isoindol-2-yl)-3-methylphenyl]methyl]cyclopropyl]amino]-2-oxoethyl]-4-methoxybenzoic acid	568519: Antagonist activity at human EP4 receptor expressed in HEK293 cells assessed as PGE2-induced cAMP accumulation by scintillation proximity assay	ki	0.0002	uM
N-[1-[[4-(4,9-diethoxy-3-oxo-1H-benzo[f]isoindol-2-yl)-3-methylphenyl]methyl]cyclopropyl]-2-(3-methoxy-2-pyridinyl)acetamide	568519: Antagonist activity at human EP4 receptor expressed in HEK293 cells assessed as PGE2-induced cAMP accumulation by scintillation proximity assay	ki	0.0002	uM
N-[[4-(4,9-diethoxy-3-oxo-1H-benzo[f]isoindol-2-yl)phenyl]methylsulfonyl]-2-phenylacetamide	316652: Binding affinity to human EP4 receptor expressed in HEK293 cells	ki	0.0003	uM
2-(2,6-dichlorophenyl)-N-[[4-(5,9-diethoxy-6-oxo-8H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylphenyl]methylsulfonyl]acetamide	316652: Binding affinity to human EP4 receptor expressed in HEK293 cells	ki	0.0003	uM
N-[[4-(5,9-diethoxy-6-oxo-8H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylphenyl]methylsulfonyl]-2-(2-ethoxyphenyl)acetamide	316652: Binding affinity to human EP4 receptor expressed in HEK293 cells	ki	0.0003	uM
N-[[4-(5,9-diethoxy-6-oxo-8H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylphenyl]methylsulfonyl]-2-[2-(difluoromethoxy)phenyl]acetamide	316652: Binding affinity to human EP4 receptor expressed in HEK293 cells	ki	0.0003	uM
2-(2-chlorophenyl)-N-[[4-(5,9-diethoxy-6-oxo-8H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylphenyl]methylsulfonyl]acetamide	316652: Binding affinity to human EP4 receptor expressed in HEK293 cells	ki	0.0003	uM
4-[[4-[4-(difluoromethoxy)phenyl]anilino]methyl]-5-methyl-N-(2-methylphenyl)sulfonylfuran-2-carboxamide	1139728: Displacement of [3H]PGE2 from human prostanoid EP4 receptor expressed in cell membranes by scintillation counting	ki	0.0003	uM
4-[(1S)-1-[[1-[(3,5-dibromophenyl)methyl]-2,3-dihydroindole-7-carbonyl]amino]ethyl]benzoic acid	549650: Displacement of [3H]PGE2 from human prostanoid EP4 receptor expressed in HEK293-EBNA cells after 60 mins by scintillation counting	ki	0.0003	uM
4-[(1S)-1-[[1-[(3,4-dichlorophenyl)methyl]-2,3-dihydroindole-7-carbonyl]amino]ethyl]benzoic acid	549650: Displacement of [3H]PGE2 from human prostanoid EP4 receptor expressed in HEK293-EBNA cells after 60 mins by scintillation counting	ki	0.0003	uM
4-[1-[[5-chloro-1-[[4-(trifluoromethyl)phenyl]methyl]indole-7-carbonyl]amino]cyclopropyl]benzoic acid	484030: Displacement of [3H]PGE2 from human prostanoid EP4 receptor expressed in HEK293-EBNA cells after 60 mins by scintillation counting	ki	0.0003	uM
1-(2,6-dichlorophenyl)sulfonyl-3-[1-[[4-(4,9-diethoxy-3-oxo-1H-benzo[f]isoindol-2-yl)-3-methylphenyl]methyl]cyclopropyl]urea	568519: Antagonist activity at human EP4 receptor expressed in HEK293 cells assessed as PGE2-induced cAMP accumulation by scintillation proximity assay	ki	0.0003	uM
1-[1-[[4-(4,9-diethoxy-3-oxo-1H-benzo[f]isoindol-2-yl)-3-methylphenyl]methyl]cyclopropyl]-3-(2,6-dimethoxyphenyl)sulfonylurea	568519: Antagonist activity at human EP4 receptor expressed in HEK293 cells assessed as PGE2-induced cAMP accumulation by scintillation proximity assay	ki	0.0003	uM
N-[[4-(4,9-diethoxy-3-oxo-1H-benzo[f]isoindol-2-yl)-3-methylphenyl]methylsulfonyl]-2-phenylacetamide	316652: Binding affinity to human EP4 receptor expressed in HEK293 cells	ki	0.0003	uM
4-[2-[(2R)-2-[(E,3S)-3-(1-butylcyclobutyl)-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl]ethyl]benzoic acid	320754: Agonist activity at human EP4 receptor by cAMP assay	ec50	0.0003	uM
4-[(1S)-1-[[1-[(4-phenylphenyl)methyl]-2,3-dihydroindole-7-carbonyl]amino]ethyl]benzoic acid	549650: Displacement of [3H]PGE2 from human prostanoid EP4 receptor expressed in HEK293-EBNA cells after 60 mins by scintillation counting	ki	0.0003	uM
2-(2-chlorophenyl)-N-[1-[[4-(4,9-diethoxy-3-oxo-1H-benzo[f]isoindol-2-yl)-3-methylphenyl]methyl]cyclopropyl]acetamide	568519: Antagonist activity at human EP4 receptor expressed in HEK293 cells assessed as PGE2-induced cAMP accumulation by scintillation proximity assay	ki	0.0003	uM
3-[4-[[1-(2-methoxyphenyl)cyclopropanecarbonyl]sulfamoylmethyl]phenyl]-N,N,5,7-tetramethyl-1-benzothiophene-2-carboxamide	552143: Binding affinity to EP4 receptor	ki	0.0003	uM
2-(2,4-dichlorophenyl)-N-[1-[[4-(4,9-diethoxy-3-oxo-1H-benzo[f]isoindol-2-yl)-3-methylphenyl]methyl]cyclopropyl]acetamide	568519: Antagonist activity at human EP4 receptor expressed in HEK293 cells assessed as PGE2-induced cAMP accumulation by scintillation proximity assay	ki	0.0003	uM
N-[2-[4-(4,9-diethoxy-3-oxo-1H-benzo[f]isoindol-2-yl)-3-methylphenyl]ethyl]-2-(2-methoxyphenyl)acetamide	568519: Antagonist activity at human EP4 receptor expressed in HEK293 cells assessed as PGE2-induced cAMP accumulation by scintillation proximity assay	ki	0.0003	uM
4-[[5-[3-(hydroxymethyl)phenyl]-2-methylbenzoyl]amino]-3,5-dimethylbenzoic acid	1272648: Antagonist activity at human EP4 receptor expressed in HEK293 cells assessed as inhibition of PGE2-stimulated cAMP production after 1 hr by HTRF assay	ic50	0.0003	uM
N-benzylsulfonyl-3-[[(1S)-2-(4,5-diphenyl-1,3-oxazol-2-yl)cyclohex-2-en-1-yl]methyl]benzamide	238968: Inhibition of [3H]PGE-2 binding to human prostanoid EP4 receptor	ki	0.0003	uM
N-[[4-(4,9-diethoxy-3-oxo-1H-benzo[f]isoindol-2-yl)phenyl]methylsulfonyl]-2-(2,5-dimethoxyphenyl)acetamide	316652: Binding affinity to human EP4 receptor expressed in HEK293 cells	ki	0.0004	uM

CTD chemical–gene interactions

90 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	affects cotreatment, increases expression, decreases expression, decreases reaction	6
Valproic Acid	affects cotreatment, increases expression, decreases expression	6
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression, increases stability	4
Benzo(a)pyrene	increases expression, decreases expression	3
nickel sulfate	increases response to substance, increases secretion, increases chemical synthesis, increases reaction, increases expression (+1 more)	2
mercuric bromide	affects cotreatment, increases expression	2
AH 23848	affects binding, affects cotreatment, decreases reaction, decreases activity	2
Vehicle Emissions	affects cotreatment, decreases expression, increases expression	2
Cisplatin	decreases expression, increases expression	2
Lipopolysaccharides	decreases reaction, increases expression, affects response to substance, affects cotreatment	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Tobacco Smoke Pollution	decreases expression, increases expression	2
Dinoprostone	increases reaction, decreases reaction, increases expression, increases activity, increases chemical synthesis (+2 more)	2
Particulate Matter	decreases expression, increases abundance	2
aristolochic acid I	increases expression	1
bisphenol A	decreases expression	1
diethyl phthalate	affects cotreatment, decreases expression, decreases reaction	1
2-methyl-4-isothiazolin-3-one	increases expression	1
diisononyl phthalate	affects cotreatment, decreases expression, decreases reaction	1
trichostatin A	increases expression	1
2-butenal	decreases expression	1
3,4-dichloroaniline	decreases expression	1
afimoxifene	increases expression, affects reaction	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
cobaltous chloride	decreases expression	1
butyraldehyde	increases expression	1
3,4,5,3’,4’-pentachlorobiphenyl	increases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
ochratoxin A	increases expression	1
diisobutyl phthalate	affects cotreatment, decreases expression, decreases reaction	1

ChEMBL screening assays

288 unique, capped per target: 207 binding, 80 functional, 1 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1009665	Binding	Inhibition of EP4 receptor	Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP(1) receptor antagonist for the treatment of inflammatory pain. — Bioorg Med Chem Lett
CHEMBL1047106	Functional	Inhibition of EP4 expressed in HEK293 cells assessed as inhibition of PGE2-induced cAMP production	Discovery and optimization of CRTH2 and DP dual antagonists. — Bioorg Med Chem Lett
CHEMBL4326154	ADMET	Displacement of [3H]prostaglandin E2 from recombinant human full length EP4 receptor expressed in Chem-1 cell membranes after 60 mins by liquid scintillation counting	Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl. — J Med Chem

Cellosaurus cell lines

11 cell lines: 7 cancer cell line, 4 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B7YY	Abcam Raji PTGER4 KO	Cancer cell line	Male
CVCL_B9ZP	Abcam THP-1 PTGER4 KO	Cancer cell line	Male
CVCL_C0TM	ACTOne PTGER4	Transformed cell line	Female
CVCL_C7BD	Abcam PC-3 PTGER4 KO	Cancer cell line	Male
CVCL_E2I6	HAP1 PTGER4 (-) 1	Cancer cell line	Male
CVCL_E2I7	HAP1 PTGER4 (-) 2	Cancer cell line	Male
CVCL_H367	293 c18/EP4	Transformed cell line	Female
CVCL_KZ63	PathHunter HEK 293 PTGER4 beta-arrestin	Transformed cell line	Female
CVCL_LB19	PathHunter U2OS PTGER4 Activated GPCR Internalization	Cancer cell line	Female
CVCL_LB20	PathHunter U2OS PTGER4 beta-arrestin	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.